Date: Tuesday, June 4, 2019
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA; CD272) has been implicated in the regulation of autoimmune and may potentially play an important role in alloimmune responses. We investigated the effect of anti-BTLA monoclonal antibody (6B2) in the survival of fully MHC-mismatched murine cardiac allograft transplantation.
*Methods: CBA male mice underwent transplantation of C57BL/6(B6) hearts and received a single dose (100μg) of 6B2 on the day of transplantation (day 0) or four doses on day 0, 3, 6 and 9. Adoptive transfer and flow cytometry study was performed to determine whether regulatory cells were generated. Cell-proliferation and cytokine assessments were also performed.
*Results: CBA recipients with no treatment rejected B6 cardiac graft acutely (median survival time [MST], 7 days). CBA mice treated with one and four doses of 6B2 prolonged allograft survival (MSTs, 46 and >100 days, respectively). Secondary CBA recipients showed prolonged survival of B6 hearts after treatments with whole splenocytes from primary combination-treated CBA recipients carrying B6 cardiac allografts for 30 days (MST, >30 days). Flow cytometry studies showed an increased CD4+CD25+Foxp3+ cell population in splenocytes from 6B2-treated mice. Cell proliferation of splenocytes was suppressed in 6B2-treated mice compared to that from splenocytes of untreated recipients.
*Conclusions: Anti-BTLA monoclonal antibody (6B2) could induce hyporesponsiveness of fully MHC-mismatched cardiac allografts and generation of CD4+CD25+Foxp3+ regulatory T cells.
To cite this abstract in AMA style:Yin E, Uchiyama M, Yamamoto Y, Niimi M. Anti-CD272 Antibody (6B2) Induced Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allograft [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/anti-cd272-antibody-6b2-induced-indefinite-survival-of-fully-mhc-mismatched-murine-cardiac-allograft/. Accessed September 23, 2021.
« Back to 2019 American Transplant Congress